Stocklytics Platform
Asset logo for symbol WGS
GeneDx Holdings
WGS65
$73.73arrow_drop_down6.10%-$4.79
High Growth
Asset logo for symbol WGS
WGS65

$73.73

arrow_drop_down6.10%

Performance History

Chart placeholder
Key Stats
Open$78.36
Prev. Close$76.92
EPS-3.09
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range75.47
82.14
52 Week Range1.16
88.77
Ratios
EPS-3.09

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About GeneDx Holdings (WGS)

Sema4 Holdings Corp. (WGS) is a leading precision medicine company that specializes in genomic and clinical data analysis. The company was founded in 2017 and is headquartered in Stamford, Connecticut. Sema4 uses advanced genomic sequencing technology to analyze a patient's DNA and identify potential genetic causes of disease. By leveraging this information, Sema4 aims to provide personalized treatment options and improve patient outcomes.
The stock price history of Sema4 Holdings Corp. (WGS) has shown steady growth since its initial public offering. The company's stock has experienced consistent upward movement, reflecting the market's confidence in Sema4's innovative approach to precision medicine. Investors have responded positively to the company's strong financial performance and promising growth prospects.
Websitecall_made
Sector
Healthcare
Industry
Health Information Services
CEO
Ms. Katherine A. Stueland
Headquarters
Stamford
Employees
1100
Exchange
NASDAQ
add GeneDx Holdings to watchlist

Keep an eye on GeneDx Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for GeneDx Holdings (WGS)?

For GeneDx Holdings (WGS), the 52-week high is $88.77, which is 20.4% from the current price. The 52-week low is $1.16, the current price is 6.26K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is GeneDx Holdings's (WGS) price per share?

The current price per share for GeneDx Holdings (WGS) is $73.73. The stock has seen a price change of -$4.79 recently, indicating a -6.1% change. This reflects the stock's recent market performance and investor sentiment.
help

Is GeneDx Holdings (WGS) a growth stock?

GeneDx Holdings (WGS) has shown an average price growth of -3.55% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying GeneDx Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is GeneDx Holdings (WGS) stock price performance year to date (YTD)?

As of the latest data, GeneDx Holdings (WGS) has a year-to-date price change of 2.69K%. Over the past month, the stock has experienced a price change of 23.4%. Over the last three months, the change has been 117.94%. Over the past six months, the figure is 245.34%.
help

Is GeneDx Holdings (WGS) a profitable company?

GeneDx Holdings (WGS) has a net income of -$175.77M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 29.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.11% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $202.57M, although specific revenue growth data is currently not available. The gross profit is $60.62M. Operating income is noted at -$163.66M. Furthermore, the EBITDA is -$38.76M.
help

What is the market capitalization of GeneDx Holdings (WGS)?

GeneDx Holdings (WGS) has a market capitalization of $2.03B. The average daily trading volume is 74.69, indicating the stock's liquidity and investor engagement.

News

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
MID-CAP STOCKS
GLOBALSTAR
V.F. CORP
MADRIGAL PHARMACEUTICALS
FINANCIAL RESULTS
BUSINESS UPDATES
Nov 3, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Opko Health sells $823k of GeneDx holdings shares - Investing.com
OPKO HEALTH
GENEDX HOLDINGS CORP.
INSIDER TRADING
STOCK SALE
Jul 19, 2024

Opko Health sells $823k of GeneDx holdings shares - Investing.com

Expert Ratings For GeneDx Hldgs - Benzinga
GENEDX HLDGS
ANALYST RATINGS
PRICE TARGETS
Jul 17, 2024

Expert Ratings For GeneDx Hldgs - Benzinga

The Latest Analyst Ratings For GeneDx Hldgs
ANALYST RATINGS
Jun 26, 2024

The Latest Analyst Ratings For GeneDx Hldgs

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
HEALTH
PARTNERSHIPS
Jun 10, 2024

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
HEALTH
Jun 5, 2024

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level